Omnicell (NASDAQ:OMCL) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research note issued to investors on Friday.

OMCL has been the subject of several other reports. Benchmark reiterated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America reiterated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Craig Hallum raised their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Finally, Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $50.83.

Omnicell Stock Performance

NASDAQ:OMCL opened at $45.67 on Friday. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The firm’s 50-day simple moving average is $44.20 and its 200 day simple moving average is $36.89. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of -117.10, a P/E/G ratio of 43.97 and a beta of 0.81.

Institutional Trading of Omnicell

A number of hedge funds have recently added to or reduced their stakes in OMCL. Geode Capital Management LLC lifted its stake in shares of Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after acquiring an additional 2,877 shares during the last quarter. Pier Capital LLC acquired a new stake in shares of Omnicell during the third quarter valued at about $5,859,000. SageView Advisory Group LLC bought a new stake in shares of Omnicell during the third quarter worth about $480,000. ArrowMark Colorado Holdings LLC increased its stake in shares of Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock valued at $49,742,000 after buying an additional 243,353 shares during the period. Finally, Verition Fund Management LLC acquired a new position in shares of Omnicell in the third quarter valued at approximately $388,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.